Pharmacodynamic effects following co-administration of cannabinoids and opioids: a scoping review of human experimental studies
- PMID: 38561178
- DOI: 10.1093/pm/pnae024
Pharmacodynamic effects following co-administration of cannabinoids and opioids: a scoping review of human experimental studies
Abstract
Background: Cannabinoids are increasingly used in the management of chronic pain. Although analgesic potential has been demonstrated, cannabinoids interact with a range of bodily functions that are also influenced by chronic pain medications, including opioids.
Objective: We performed a scoping review of literature on the pharmacodynamic effects following the co-administration of cannabinoids and opioids.
Methods: We systematically searched EMBASE, PubMed, and PsycINFO for studies that experimentally investigated the co-effects of cannabinoids and opioids in human subjects. Available evidence was summarized by clinical population and organ system. A risk of bias assessment was performed.
Results: A total of 16 studies met the inclusion criteria. Study populations included patients with chronic non-cancer and cancer pain on long-term opioid regimens and healthy young adults without prior exposure to opioids who were subject to experimental nociceptive stimuli. Commonly administered cannabinoid agents included Δ9-tetrahydrocannabinol and/or cannabidiol. Co-administration of cannabinoids and opioids did not consistently improve pain outcomes; however, sleep and mood benefits were observed in chronic pain patients. Increased somnolence, memory and attention impairment, dizziness, gait disturbance, and nauseousness and vomiting were noted with co-administration of cannabinoids and opioids. Cardiorespiratory effects following co-administration appeared to vary according to duration of exposure, population type, and prior exposure to cannabinoids and opioids.
Conclusions: The available evidence directly investigating the pharmacodynamic effects following co-administration of cannabinoids and opioids for non-analgesic outcomes is scarce and suffers from a lack of methodological reporting. As such, further research in this area with comprehensive methodologic reporting is warranted.
© The Author(s) 2024. Published by Oxford University Press on behalf of the American Academy of Pain Medicine. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Similar articles
-
Opioid-sparing effect of cannabinoids for analgesia: an updated systematic review and meta-analysis of preclinical and clinical studies.Neuropsychopharmacology. 2022 Jun;47(7):1315-1330. doi: 10.1038/s41386-022-01322-4. Epub 2022 Apr 22. Neuropsychopharmacology. 2022. PMID: 35459926 Free PMC article.
-
Current evidence of cannabinoid-based analgesia obtained in preclinical and human experimental settings.Eur J Pain. 2018 Mar;22(3):471-484. doi: 10.1002/ejp.1148. Epub 2017 Nov 21. Eur J Pain. 2018. PMID: 29160600 Review.
-
The role of carbon monoxide, heme oxygenase 1, and the Nrf2 transcription factor in the modulation of chronic pain and their interactions with opioids and cannabinoids.Med Res Rev. 2021 Jan;41(1):136-155. doi: 10.1002/med.21726. Epub 2020 Aug 20. Med Res Rev. 2021. PMID: 32820550 Review.
-
Opioids for Chronic Noncancer Pain: A Systematic Review and Meta-analysis.JAMA. 2018 Dec 18;320(23):2448-2460. doi: 10.1001/jama.2018.18472. JAMA. 2018. PMID: 30561481 Free PMC article.
-
Evaluation of the effects of CBD hemp extract on opioid use and quality of life indicators in chronic pain patients: a prospective cohort study.Postgrad Med. 2020 Jan;132(1):56-61. doi: 10.1080/00325481.2019.1685298. Epub 2019 Nov 12. Postgrad Med. 2020. PMID: 31711352 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous